Skip to main content
News Icon

COVIMMUNE being funded

A new consortium COVIMMUNE under the direction of Prof. Eicke Latz, speaker of the cluster of Excellence ImmunoSensation2 is being funded with around 2 Million Euros by the Federal Ministry of Education and Research (BMBF). The project "Understanding divergent host reactions to SARS-CoV-2 infections by precision immunology" (COVIMMUNE) brings together clinical researchers at the University Hospital Bonn who are involved in COVID-19 patient care with basic scientists with immunological expertise from the University of Bonn.

"We want to find out the connection between the mechanisms of the immune response to the SARS-CoV-2 infection and the clinical course of the disease," says Prof. Dr. Eicke Latz. Around two dozen personalities from disciplines such as virology, internal medicine, intensive care medicine, pulmonology, neurology, immunology, blood coagulation, bioinformatics and systems biology are involved. Together they want to contribute to a better understanding of the different course of the disease in SARS-CoV-2 infections. Prof. Natalio Garbi heads the sub-project of the consortium on adaptive immunity. He says: "We want to test whether the interaction of the innate and the acquired (adaptive) immune response is the key to eliminating the infection and developing long-term immunity without long-term health consequences."

The aim is to find out how the SARS-CoV-2 virus can trigger a misdirected immune response and what role this plays in severe COVID-19 disease courses. Furthermore, a clinical study will investigate which factors cause long-term damage to the lungs and the nervous system. Prof. Dr. Michael Heneka, whose sub-project in the consortium is looking at the secondary diseases of the lungs and the central nervous system caused by COVID-19, says: "It is not yet well understood how infection with the SARS-CoV-2 virus can trigger such secondary diseases. We want to examine these relationships in a clinical study in order to be able to offer better treatment options."


Contact

Prof. Dr. Eicke Latz

Institute of Innate Immunity, University of Bonn

Phone: 0228/287-51223

E-Mail: eicke.latz@uni-bonn.de

Related news

Children in the lab at "Girls' and Boys' Day 2026"

News categories: Outreach

Girls' & Boys' Day at ImmunoSensation³

The annual "Girls' & Boys' Day" (former "Girls' day") sets out to introduce children and young addults to careers their respective gender is still underrepresented in. To celebrate this special day and offer insights into the work of a biomedical researcher, we welcomed students from all over Germany to our laboratories. Besides hands-on science, career options and perspectives in research were discussed.
View entry
PM Immunity Nebeling

News categories: Publication

Study reveals dynamic interactions between brain tumors and immune cells

Glioblastoma, the most common and aggressive brain tumor in adults, is difficult to treat because this cancer can invade the surrounding brain tissue and spread far beyond the original tumor mass. Researchers from the DZNE, the University Hospital Bonn (UKB), and ImmunoSensation³ at the University of Bonn have observed this infiltration process in the living brain using high-tech microscopy. Their study is based on research in mice with a form of brain tumor that closely resembles human glioblastoma.
View entry
Nora Möhn

News categories: Publication

New Findings on Immunotherapy for a Rare Brain Infection

Progressive multifocal leukoencephalopathy (PML) is a rare but very serious brain disease. It is caused by the reactivation of the widespread JC virus when the immune system is severely weakened. There is currently no targeted antiviral therapy available, which is why new treatment approaches are urgently needed. In recent years, so-called immune checkpoint inhibitors have been increasingly used; these “unlock” the immune system and reactivate the body’s own immune cells. The results were recently published in the journal JAMA Neurology.
View entry

Back to the news overview